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Abstract
Background: Although liver resection has long been established for selected patients with benign hepatic disease,
the success of surgical treatment of these patients cannot be evaluated exclusively through postoperative
morbidity and mortality. Therefore, the aim of the study was to prove the safety of liver resection in the treatment
of benign liver tumors and to evaluate the effect of surgical treatment on the patients’ qauality of life.
Methods: A total of 146 patients who underwent liver resection because of benign liver tumors were included in
this study. Postoperative outcome was assessed and patients evaluated their quality of life before surgery and at
the present time using the European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core-30 (QLQ C-30).
Results: The rate of serious (> grade 2) complications was 4.1% with no postoperative death. The quality of life
assessment revealed an overall improvement of general health status after resection (0.7 vs. 0.56, p < 0.001) and
additionally a significant reduction of 6 out of 9 symptoms. Furthermore, compelling benefits in the patients’ social
and emotional coping could be detected after surgery.
Conclusions: Liver resection for benign liver disease is a safe procedure and leads to a significant improvement of
quality of life in selected patients.
Background
In recent years benign liver tumors have been diagnosed
in larger numbers due to advantages in diagnostic ima-
ging modalities [1-4]. Most common benign entities are
hemangioma, followed by focal nodular hyperplasia
(FNH) and adenoma, which together represent more
than 80% of all benign liver tumors [3-5]. Rare benign
liver diseases include for instance parasitic liver cysts,
cystadenoma, caroli’s disease and angiomyolipoma.
Although data are heterogenous incidence of simple
liver cysts is estimated to be approximately 5% [3-5].
Despite widespread availability of imaging modalities the
differentiation between benign and malignant liver
tumors remains a diagnostic challenge. While the
accurate distinction between FNH and adenoma, as well
as hepatocellular carcinoma, may be difficult, it is essen-
tial with regard to the appropriate treatment strategy
[6]. Percutaneous liver biopsy often has limited benefit
and must be regarded as contraindicated, especially in
hypervascular tumors such as hemangioma [7].
Most benign tumors do not require aggressive treat-
ment and the indication for resection of benign hepatic
lesions remains controversial [3,4,8,9]. Today, hepatect-
omy is an accepted treatment for primary and secondary
liver malignancies with low mortality-rates and morbid-
ity of less than 30% [3,4,10,11], but major liver surgery
for benign liver disease remains under discussion. Cur-
rently accepted indications for surgical resection of a
benign liver tumor include suspicion of malignancy and
severe or progressive tumor-related symptoms [3,4,11].
Large or growing hepatic adenomas should also be
resected based on the risk of malignant degeneration
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(e.g. echinococcus) a resection of the cyst is also
recommended.
Postoperative morbidity and mortality as well as
recurrence rate are the main factors evaluating the clini-
cal outcome of patients undergoing major liver resec-
tion. However, a number of biological, social and
clinical parameters that are meaningful for the patient
are not reflected by these data, especially after resection
of benign liver tumors. Based on the modern concepts
of health-related quality of life (QoL) several question-
naires, such as the EORTC-QLQ-C30, have been devel-
oped in recent years, measuring the subjective outcome
for patients after hepatobiliary surgery [12-15]. Assess-
ment of quality of life, such as disease-free or overall
survival, has become an important tool for the assess-
ment of cancer patients [16,17], but no study has so far
evaluated the quality of life liver resection has on
patients with benign liver tumors.
The aim of the study was therefore to evaluate the
postoperative outcome of patients who underwent liver
resection due to benign liver disease in a primary hepa-
tobiliary center. Furthermore, this study represents the
first evaluation of quality of life after resection of benign
hepatic tumors overall.
Methods
Between April 2002 and May 2008 all patients who
underwent liver resection for benign liver disease at our
center were included in the study. Patients were
excluded in case of occurrence of any malignant disease
during the follow-up period.
For all patients eligible for the study the following data
were collected in a prospective database: demographics,
indication, details of surgical procedure, postoperative
complications according to the score by Dindo et al.
[18], follow up, including recurrence rate and survival,
as well as quality of life before surgery and at the pre-
sent time.
Indications for surgery were suspicion of malignancy,
severe or progressive symptoms, diagnosis of parasitic
liver cysts as well as diagnosis or suspicion of adenoma.
Surgical procedures for benign liver tumors included:
left and right hemihepatectomy, extended left and right
hemihepatectomy, unisegmentectomy, plurisegmentect-
omy, atypical resection and combinations of these tech-
niques. Patients undergoing laparoscopic fenestrations of
liver cysts were excluded from the present analysis;
however, patients who underwent formal liver resection
for liver cysts or cystic liver tumors were included.
Quality of life
Q u a l i t yo fl i f eb e f o r ea n da f t e rs u r g e r yw a sa s s e s s e db y
sending a quality of life questionnaire to all patients
included in this study after recovery from surgery.
The patients were asked to evaluate their quality of
life before surgery and at present time. Since there is
no specific questionnaire for benign liver tumors avail-
able, the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire
Core-30 (QLQ C-30, Version 3.0) was used. This
questionnaire is normally used in clinical cancer trials,
but also adequate for assessing quality of life in
patients with benign liver tumors, whose symptoms
and discomfort are often similar to cancer patients.
The questionnaire consists of 30 items incorporating 5
functional scales (physical, role, social, emotional, cog-
nitive), 9 symptom scales (fatigue, nausea/vomiting,
pain, dyspnoea, insomnia, loss of appetite, constipa-
tion, diarrhea, financial difficulties) and a global health
scale [19]. Beyond the questionnaire all patients were
asked if they would undergo liver resection for a
benign hepatic lesion again, based on their present
quality of life.
Ethics
For this study ethical approval was obtained from the
institutional ethical committee (EA2/047/09, Ethical
committee of the Charité, University Clinic, Berlin) and
all patients gave informed consent prior to the enrol-
ment in the study.
Statistics
Statistical analysis was performed using PASW Statistics
18.0 (SPSS Inc., Chicago, IL) and the R statistical soft-
ware (Version 2.8.1, GNU/Linux). All quantitative data
were expressed as median and range, unless otherwise
indicated. Differences between quality of life parameters
were tested using the Wilcoxon-test for paired samples.
A p-value of less than 0.05 was regarded as statistically
significant.
Results
The study population consisted of 146 patients who had
undergone liver resection due to benign liver disease at
our center. There was an expected majority of female
patients in the study population and preoperative blood
samples did not reveal limited liver function in any of
the patients. Relevant demographic and preoperative
parameters of the entire cohort as well as the quality of
life subpopulation are summarized in Table 1.
Diagnosis and indication
Main diagnosis in the study population was FNH in 45
patients (30.8%), followed by hemangioma in 28 patients
(19.2%) and echinococcus cyst in 21 patients (14.4%).
Table 2 categorizes the diagnoses for liver resection in
this study.
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or progressive symptoms in 77 patients (52.7%), 48
patients (32.9%) underwent liver resection because
malignancy could not be completely ruled out through
preoperative measures. The remaining 21 patients
(14.4%) were resected because of echinococcus cysts.
In 115 patients (78.8%) postoperative histopathological
findings could confirm the most likely preoperative
diagnosis, whereas in 31 patients (21.2%) the preopera-
tive diagnosis turned out to be misleading.
Operative procedures
The most frequently performed operative procedure was
right hemihepatectomy in 39 cases (26.7%), followed by
atypical resection (27 patients, 18.5%) and plurisegmen-
tectomy (25 patients, 17.1%). Unisegmentectomy was
performed in 17 patients (11.6%) whereas 16 patients
(10.9%) underwent left hemihepatectomy. Extended
hemihepatectomy was required in 15 patients (10.3%)
on the right and in 7 patients (4.8%) on the left side.
The median operative time was 200 (77-517) minutes.
In 32 patients (21.9%) a pringle maneuver was
performed intraoperatively. 13 patients (8.8%) required
blood transfusions during liver resection. The median
stay on intensive care unit was 1 (0-10) day and patients
were able to leave hospital after a median stay of 9 (2-
55) days.
Postoperative complications and follow up
There were a total of 25 postoperative complications
(17.1%) and no postoperative death in the entire
cohort. 10 patients had sterile fluid collections, of
which 3 (2.0%) required percutaneous drainage. 2
patients (1.3%) suffered from postoperative bile leak-
age and required reoperation on the first postopera-
tive day. Infectious complications (e.g. wound
infection, cholangitis) occurred in 12 (8.6%) patients,
while one patient suffered a middle cerebral artery
stroke despite sufficient anticoagulation. This patient
recovered well and was sent to a neurological rehabi-
litation 16 days after surgery. The rate of serious (≥
grade 3) complications was 4.1% (6 patients) in the
study population.
During the follow-up period recurrent disease was
observed in 13 out of 146 patients, representing a recur-
rence rate of 9% for the entire cohort. 6 out of these 13
patients developed liver cysts again, leading to a disease
recurrence rate of 40% in this subpopulation, while 5
patients with FNH (11.1% of the FNH population) and
one patient each with adenoma (11.1% of the adenoma
population) and hemangioma (3.6% of the hemangioma
population) had recurrence of their liver disease. How-
ever, none of these cases were recurrences in the com-
mon sense but patients rather developed growth of
preexisting small lesions in the remnant liver based on
the fact that all of these conditions can be of multifocal
nature. After a median follow-up of 50 months (3-95
months) all patients are still alive.
Table 1 Demographics and preoperative liver values of
all patients and the Quality of Life subpopulation.
All patients
(n = 146)
QoL group
(n = 81)
Age [years] 44 (13 - 74) 46 (16-74)
Gender ratio (male : female) 37 (25.3%) :
109 (74.7%)
16 (19.8%) :
65 (80.2%)
Tumor size [mm] 65 (10 - 230) 70 (8 - 230)
Preoperative bilirubine level [mg/dl] 0.5 (0.2 - 6.2) 0.5 (0.2 - 3.0)
Preoperative AST [U/l] 24 (6 - 259) 24 (8 - 259)
Preoperative ALT [U/l] 26 (4 - 775) 25 (5 - 775)
Preoperative Quick value [%] 97 (27 - 130) 98 (27 - 130)
Values are median (range).
Table 2 Diagnosis and type of liver resection of the entire cohort and the Quality of Life (QoL) subpopulation.
All patients (n = 146) QoL group (n = 81)
Diagnosis
FNH 45 (30.8%) 27 (33.3%)
Hemangioma 28 (19.1%) 14 (17.3%)
Adenoma 9 (6.2%) 6 (7.4%)
liver cyst 15 (10.3%) 9 (11.1%)
echinococcus cyst 21 (14.4%) 9 (11.1%)
caroli’s disease 13 (8.9%) 7 (8.6%)
others* 15 (10.3%) 9 (11.1%)
Type of liver resection
hemi- or extended
hemihepatectomy
77 (52.7%) 44 (54.3%)
parenchyma-sparing
resection
69 (47.3%) 37 (45.7%)
others*: liver abscess (6 patients), cystadenoma (5 patients), angiomyolipoma (4 patients)
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A total of 81 patients (55.5% of the entire cohort) who
had returned a completed questionnaire were included
in the quality of life assessment. Details on demo-
graphic data as well as diagnosis and type of liver
resection are summarized in Table 1 and Table 2. The
main indications for surgery were the occurrence of
severe symptoms in 44 patients (50.6%) and suspicion
of malignancy in 19 patients (19.8%). Postoperative
morbidity rate was 17.2% (14 patients) and therefore
in total not significantly different from the entire
cohort. However, this subpopulation included 5 out of
6 patients with severe complications (6.2%). After a
median follow-up of 56 months (17-76 months), 9
patients (11%) had recurrent disease, mainly after
resection of benign liver cysts (4 patients = 40% of the
liver cyst population). Likewise, all demographic as
well as diagnostic and operative details of the quality
of life subpopulation revealed no significant differ-
ences compared to the parameters of the entire cohort
(data not shown). Therefore the quality of life assess-
ment may be regarded as representative for the entire
cohort.
Quality of life assessment
Statistical analysis revealed a highly significant improved
global health status after resection of benign liver tumor
in our population (0.7 vs. 0.56, p < 0.001).
The Wilcoxon test for paired samples also showed a
remarkable benefit in social (p = 0.03) and emotional
functioning (p = 0.007) after surgery, whereas no impact
on physical wellbeing and cognitive functioning was
detected.
A reduction of symptoms after operative therapy of
benign liver disease was observed in 6 out of 9 symptom
scales. Especially for the symptoms pain (0.24 vs. 0.37, p
= 0.001) and fatigue (0.3 vs. 0.41, p = 0.004) the post-
operative improvement was highly significant. A detailed
analysis of the EORTC QLQ C-30 questionnaire is sum-
marized in Table 3.
At the end of the follow-up period, 78 of 81 patients
(96.3%) would again undergo liver resection due to
benign liver disease from their present point of view.
Discussion
Despite controversial discussion about the practice of
liver surgery in benign liver disease, nowadays liver
resection is well-established as treatment of selected
patients. Despite ongoing advantages in imaging modal-
ities in recent years, there still is a considerable propor-
tion of patients with an incorrect preoperative diagnosis.
In a study by Charny et al. only 42 out of 62 preopera-
tive diagnoses (67.7%) could be confirmed postopera-
tively by histopathological examination [11]. In the
present study the percentage of patients with correct
preoperative diagnosis increased to 78.8%, largely due to
improved preoperative diagnostics. However, in a rele-
vant number of patients the differentiation between
benign and malignant hepatic lesions remains
challenging.
In the largest series in literature Feng et al. reported
on 827 liver resections for benign hepatic tumors with a
postoperative complication rate of 13.5%, showing that
liver resection can be regarded as a safe procedure [20].
Similar results were published by Charny et al. [11],
who reported on 155 patients undergoing liver resection
due to benign hepatic disease with a postoperative mor-
bidity of 21% and no postoperative death. These results
can be emphasized by the present study showing an
overall complication rate of 17.1% with a mortality of
0%. In this series a total of only 4.1% of the patients had
serious complications (≥ grade 3) which required further
intervention but all of them recovered well during the
follow-up period; however the majority of postoperative
complications can be regarded as minor. Comparable
data have recently been published by Lordan et al. [21].
In a series of 79 liver resections the rate of serious com-
plications was 1.3% and no postoperative death
occurred. This leads to the conclusion that even major
hepatic resections of benign liver tumors can be safely
performed in specialized hepatobiliary centers. This fact
might influence the decision-finding process in these
patients.
Table 3 Results of EORTC QLQ C30 questionnaire before
surgery and at present time.
before Surgery at present time p
mean SD mean SD
Global health status 0.56 0.30 0.70 0.22 0.000
Functional scales
Physical functioning 0.83 0.22 0.85 0.17 0.16
Role functioning 0.73 0.34 0.77 0.31 0.23
Emotional functioning 0.57 0.29 0.66 0.26 0.007
Cognitive functioning 0.80 0.25 0.78 0.27 0.30
Social functioning 0.66 0.36 0.75 0.29 0.03
Symptom scales
Fatigue 0.41 0.33 0.30 0.31 0.004
Nausea and vomiting 0.18 0.29 0.12 0.23 0.068
Pain 0.37 0.38 0.24 0.28 0.001
Dyspnoea 0.24 0.32 0.21 0.31 0.29
Insomnia 0.40 0.35 0.31 0.34 0.027
Appetite loss 0.19 0.32 0.11 0.23 0.033
Constipation 0.22 0.30 0.14 0.27 0.027
Diarrhoea 0.16 0.27 0.21 0.32 0.039
Financial difficulties 0.17 0.33 0.18 0.30 0.98
p< 0.05 is considered significant and in bold.
SD: Standard deviation
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recurrence rate of benign liver disease after liver resec-
tion is low. In our study 9% of the patients had recur-
rent disease and none of them required re-intervention.
This strengthens the hypothesis that according to the
standard parameters, morbidity and tumor recurrence,
hepatic resection reaches good results in the treatment
of benign liver disease. However, there are some impor-
tant aspects concerning the patients’ subjective feelings,
which are not reflected by these parameters. Different
health-related quality of life tools like the EORTC QLQ-
C30 or the short-form 36 (SF 36) have been developed
during the last 15 years in order to measure the effect
of different therapeutic strategies on patients life, mainly
in oncological patients [22-24]. These days, quality of
life tools have also been established in the evaluation of
subjective outcome of common hepatobiliary procedures
and are therefore incorporated into the decisions of clin-
icians and patients [12-14]. In a prospective longitudinal
study Poon et al. showed a significant enhancement of
quality of life in patients with hepatocellular carcinoma
after hepatectomy [12]. Similar results were presented in
another study by Martin et al. who revealed a significant
improvement in long-term quality of life after major
hepatectomy in patients with primary or metastatic liver
cancer [13]. It is widely accepted that quality of life
represents a parameter which is as important as disease-
free survival or overall survival in cancer patients [15].
Nevertheless there is hardly any data about quality of
life in patients with benign disease so far.
Although, particularly for those patients, for whom
morbidity and mortality are nots u f f i c i e n ti ne v a l u a t i n g
the therapeutic success, this study is, to our knowledge,
the first in literature that evaluates the impact of hepatic
resection on the quality of life of patients with benign
liver tumors. In several other studies it has been shown
that 80-89% of all patients with preoperative complaints
d u et ob e n i g nl i v e rd i s e a s ew e r ea s y m p t o m a t i ca f t e r
liver resection [8,11,21,25], but these studies only
focused on a selection of all patients and often referred
to a single symptom. In the present study it could be
elucidated that hepatic resection leads to a significant
improvement of global health status in the entire group
of patients with benign liver disease. Beside a reduction
of 6 out of 9 analyzed symptoms, a significant impact of
liver resection on social and emotional functioning in
these patients could be detected. The fact, that 96.3% of
the patients would undergo liver resection again from
their present point of view stresses the positive effect of
liver surgery on patients’ everyday lives. Although the
interpretation of this study might be limited due to its
retrospective character the s er e s u l t sg i v eas t r o n g
impression of the patients’ subjective outcome after
resection of benign liver tumors and underline the
benefit of surgical treatment from the patients’ point of
view. The immanent bias of the return rate of the ques-
tionnaires in retrospective studies cannot be avoided in
t h ep r e s e n ts t u d ya sw e l l .H o w e v e r ,t h eQ u a l i t yo fL i f e
subpopulation can be regarded as representative for the
entire cohort and therefore all conclusions can be
drawn for all the patients in this study.
Conclusions
In conclusion, this study demonstrates that liver resec-
tion due to benign liver tumor can be performed safely
in a specialized hepatobiliary center. Furthermore, this
study is the first in literature to show that surgical treat-
ment of benign liver lesions might lead to an improve-
ment in quality of life by reducing symptoms and
improving emotional and social functioning. Further
prospective studies are crucial in order to support these
results and thus might affect the decision-finding pro-
cesses in patients with benign liver tumors.
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